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Summary 
Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis 
(MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients 
who relapse follow- ing transplant. We hereby report on the management and outcome of 202 patients who 
relapsed post allo-HSCT for MF. 
  
Over the last decade, there has been a significant increase in the number of patients with Myelofibrosis (MF) undergoing 
Allogeneic Haematopoietic Stem Cell Transplantation (allo- HSCT). The European Society for Blood and Marrow Trans- 
plantation (EBMT) registry reported on 181 episodes in 2004 which had risen considerably to 559 episodes in 2014. 
Current practice often adheres to consensus European LeukaemiaNet (ELN)/EBMT guidelines that suggest consideration 
towards transplantation in intermediate-2- or high-risk disease, as defined by the International Prognostic Scoring System 
(IPSS), and for patients who are <70 years of age. Moreover, patients with intermediate-1-risk disease and age <65 years 
could be considered if they present with either refractory, transfusion- dependent anaemia, or a percentage of blasts in 
peripheral blood (PB) >2%, or adverse cytogenetics (Kro€ger et al, 2015). 
Despite the advent of many novel agents in MF, allo-HSCT remains the only known curative approach (reviewed in 
McLornan et al, 2012). However, disease relapse remains a sig- nificant barrier to successful outcome. Long-term results 
from the first prospective study of reduced intensity conditioned (RIC) allo-HSCT co-ordinated by the EBMT suggested a 
sig- nificant relapse risk of up to 22% at 3 years and approximately 28% at 5 years, although historically relapse rates 
were higher (Kro€ger  et al,  2009a).  We  hereby  report  on  a  retrospective analysis of 202 patients with MF registered in 
the EBMT data- base who have relapsed following allo-HSCT. 
 
Methods 
This was a retrospective, multicentre, EBMT registry-
based analysis. All patients whose transplant data are 
reported to the EBMT by participating centres provide 
informed consent to  use the information for 
anonymised research. Patient selection 
was performed by identifying adult patients who underwent first allo-HSCT for MF between the years 2000–
2014, using either RIC or myeloablative conditioning (MAC). Those with documented and dated relapse (after 
Day +30) and sufficient clinical details were analysed. Statistical analyses were per- formed with SPSS 22 
(IBM, Armonk, NY, USA). Patient-, dis- ease- and transplant-related variables were expressed as median and 
range for continuous variables and frequencies for categorical variables. Overall Survival (OS) was calculated from 
the date of documented relapse until death or last observation alive. Patients alive at their last follow-up were 
censored. This study was performed in accordance with the principles of the Declaration of Helsinki and 
approved by the Chronic Malig- nancies Working Party of the EBMT. 
 
Results 
From the registry, a total of 251 relapsed patients were identi- fied within an entire patient cohort of 1371, giving an 
esti- mated relapse incidence of 18·3%, albeit dependent on adequate reporting. For this analysis, we excluded 
cases with insufficient clinical information, umbilical cord blood and haploidentical transplants and, hence, a total of 
202 patients were included (Table I). A total of 165 patients had a diagno- sis of primary MF and 37 secondary MF 
at the time of trans- plant. The cohort consisted of 133 males and 69 females with  a median age at transplantation 
of 55 years (range, 22–69 years). Sixty-six (33%) patients underwent MAC and 136 (67%) patients had RIC. The 
most frequent conditioning reg- imens across the entire cohort were fludarabine/busulphan (Flu/Bu; 36%), 
fludarabine/melphalan (Flu/Mel; 13%) and busulphan/cyclophosphamide (BuCy; 6%). The most com-  mon agent 
for in vivo T-cell depletion was antithymocyte 
  
globulin (ATG). No ex vivo T-cell depletion was 
reported. The main source of haematopoietic stem 
cells (HSC) was peripheral blood (175 patients; 87%) 
whereas 27 (13%) received BM-derived HSC. Donors 
were human leucocyte antigen-matched related (n = 
107) or unrelated [matched/ mismatched (n = 95)] 
(Table I). 
The median time from diagnosis of MF to transplant  
was  28 months (range, 2–321 months). The median  
time  to relapse  was  relatively  short,  at  7·1 months  
(range  1·4–  111 months), with a median OS from the 
time of relapse of 22·9 months for the entire cohort 
[95% confidence interval (CI) 16–29·6; Fig 1A]. 
Collectively, without treatment strati- fication, there 
was a significant difference in survival out- come for 
those relapsing <7·1 months post allo-HSCT [median 
survival 12·9 months (95% CI 27·2–44·6)] com-  pared 
to those relapsing after 7·1 months following the initial 
allo-HSCT episode [median survival 36·9 months 
(95% CI 42·8–62·8); Log Rank Mantel Cox: P < 0·002]. 
Disease dura- tion prior to allo-HSCT did not 
significantly affect outcome post-relapse. 
Heterogeneous practice existed regarding 
management  of the relapse episode and was 
documented in 165 patients (82%). A total of 47 
(23%) patients received a donor 
lymphocyte infusion (DLI) alone (median survival 
estimate, 76 months); 23 (11%) had chemotherapy 
alone (complete regimen details not documented; 
median survival approxi- mately 23 months) whereas 
18 (20%) patients had DLI com- bined with 
chemotherapy. Fifty-one (25%) patients  underwent   
2nd   allo-HSCT   alone   (median   survival    26·9 
months) and 26 (13%) underwent DLI and 2nd allo- 
HSCT (median survival estimate, 54 months). The  
median time to receive DLI in the entire  cohort  was 
relatively short  at 43 days. Most frequent conditioning 
regimens for 2nd allografts were FluBu and 
fludarabine/ATG  (Flu/ATG). Active management – if 
any- was not documented for 37 (18%) patients and 
hence was not analysed. Survival median estimates 
are highlighted in Table SI for all groups. The med- ian 
OS from the time of relapse for those receiving  DLI  
alone, DLI followed by 2nd allo-HSCT or 2nd allo-
HSCT is demonstrated in Fig 1B. 
 
Discussion 
Treatment of relapse  evidently  presents  huge  
challenges and the heterogeneous management 
strategies highlighted reflects current practice. Direct 
comparison between 
 
Table I. Patient characteristics (n = 202). 
 
Characteristic n 
 
 
Median age, years (range) 55 (22–69) 
Gender 
Male 133 
Female 69 
Diagnosis at time of transplant 
Primary myelofibrosis 165 
Secondary myelofibrosis 37 
Median time from diagnosis to transplant, months (range) 28 (2–
321) 
Median time to relapse post-transplant, months (range)  7·1 (1·4–
111) Median follow-up post-transplant for patients alive, months (range)
 52·5 (4–
116) Donor type 
Matched related 107 
Unrelated matched 35 
Unrelated mismatched/degree of match not stated 60 
Conditioning 
 
 
Myeloablative 66 
  
Reduced intensity 136 
Stem cell source  
Bone marrow 27 
Peripheral blood 175 
Graft-versus-host disease during first transplant  
Acute  
No graft-versus-host disease 122 
Grade 1 34 
Grade 2–4 37 
Missing, ungraded or unknown 9 
Chronic  
Limited 51 
Extensive 33 
Missing 118 
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Fig 1.  (A) Cumulative overall survival post-relapse of entire cohort as estimated by the Kaplan–Meier method. Median overall 
survival from the  time of relapse of approximately 23 months for the entire  cohort (95% Confidence Intervals 16–29 6). (B)  
Cumulative  overall survival post-  relapse of those patients receiving either DLI, DLI+2nd allo-HSCT or 2nd allo-HSCT alone as 
estimated by the Kaplan–Meier method. Median overall survival from the time of relapse was approximately  76 months for the 
DLI alone cohort, 54 months for the DLI+2nd allo-HSCT cohort    and 27  months for the 2nd allo-HSCT. allo-HSCT, allogeneic 
haemopoietic stem cell transplant; DLI, donor lymphocyte infusion. [Colour figure  can be viewed at wileyonlinelibrary.com] 
 
therapeutic interventions to gauge efficacy is not 
feasible  from this analysis as bias could  well  be  
influenced  by patient performance  status,  
heterogeneous  timing  of  relapse, patient and 
physician choice  and  availability  of  either DLI or 
second allo-HSCT. No robust details were available 
concerning the dynamic IPSS or pre-transplant 
therapy and it is unknown if any of the  patients  trans- 
planted in more recent years had received JAK 
inhibitors pre-transplant. Nonetheless, this 
retrospective analysis rep- resents the largest study to 
date which documents the out- come and 
management  of  MF  patients  who  undergo  relapse 
following allo-HSCT and, despite its limitations, 
provides important and clinically relevant information. 
Survival varies markedly following relapse, in this 
study the median survival was just less than 2 
years, i.e., approx- imately 23 months. It is clear 
that earlier relapse following MF allo-HSCT has a 
much worse prognosis than later relapses, akin to 
other myeloid disorders. Moreover, our data 
importantly suggests there is a beneficial role to be 
considered for adoptive immunotherapeutic  approaches 
with DLI and/or 2nd allo-HSCT. DLI was administered to 
45% of the entire cohort overall and almost 38%  of  
patients underwent a second allograft either alone or fol- 
lowing the use of DLI. Indeed, the efficacy and safety of 
dose escalating DLI in the post allo-HSCT setting for MF 
has  previously  been  described  (Kro€ger  et al,  2009b;  
Klyuch- nikov et al, 2012). Survival following 2nd allo-
HSCT (either alone or following DLI) is encouraging, 
although conclusions regarding absolute benefits of a 
2nd transplant 
(A) 
  
procedure from this study  are  somewhat limited  as  this  most often occurs in a highly selected group  who  
survive long enough and are fit enough to undergo  such interven- tion. Furthermore, 2nd allograft following  DLI  
means  that the recipient may not have responded to  DLI  alone  and  hence direct comparisons between  the  two  
modalities  are not feasible. However, one should carefully evaluate the patient who has relapsed to decide 
whether  a  2nd  allo-  HSCT is appropriate. Klyuchnikov et al (2012) previously reported on acceptable  toxicity  
and  outcomes  in  a  cohort  of relapsed patients who proceeded to 2nd allo-HSCT, utilising an alternative donor, 
the  majority  of  whom  received fludarabine, treosulphan and ATG-based condi- tioning. 
The role of splenectomy and its effect on relapse risk and subsequent outcome remains unclear  and  was  not  
analysed in this study due to a lack of complete information on splenectomy status. A recent study has suggested 
that expo- sure to JAK1/2 inhibitors did not adversely affect post-trans- plant outcomes and that there was superior  
survival  and lower non-relapse mortality in patients who had clinical improvement with JAK1/2 inhibitors prior to 
allo-HSCT (Shanavas et al, 2016). The role of these agents in the man- agement of relapse remains intriguing, yet 
ill-defined. Janson  et al (2016) recently reported on 10 patients from a single centre who had  relapsed post MF 
allo-HSCT  (median time   to relapse 24 months; range 2·7–85·7) and who received rux- olitinib therapy (Novartis 
Pharmaceuticals, Basel, Switzer- land) at a median dose of 10 mg twice daily. The median treatment duration was 
143•5 days (range, 12–369). Although transient amelioration of disease-related constitutional symp- toms, transfusion 
burden and spleen  reduction was apparent in some, progressive disease eventually occurred in all patients. No 
significant improvement in chimerism or reduc- tion in JAK2 allelic burden quantification was evident.  Of note, all 
patients who had concomitant graft-versus-host-dis- ease (GVHD), had an amelioration or resolution of their GVHD. 
In conclusion, this retrospective study is,  to  the  best  of our knowledge, the first to describe the outcome and ‘real-world’ 
management of relapsed patients post MF allo- HSCT. Timing of relapse appears critical, with those  relapsing early having  
worse  outcomes.  Close  monitoring of chimerism and minimal residual disease would therefore  be paramount. The role of DLI 
and, where required, 2nd allo-HSCT for relapsed MF should be studied  collabora- tively as there is a suggestion of survival 
benefit for those      fit enough to undergo such a  procedure.  How  the  era  of  JAK inhibitors for the therapy of  MF  will  affect  
both  relapse risk and management, however, remains unclear. 
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